Our start-up portfolio

We've built an incredible production line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit. Our start-up portfolio secures funding from investors around the world who believe in our world class science and the power of partnership.

95+

start-ups formed across therapeutics, diagnostics and medtech

24

start-up exits to date

£3.55bn+

raised by our start-up portfolio

Myricx Bio is set to be acquired by Novartis in a deal worth up to $1.5bn

Portfolio news

From early funding by Cancer Research UK, to groundbreaking research by Ed Tate, to one of Europe's largest Series A raises of 2024, including investment from us, Myricx Bio has transformed an unconventional idea into pioneering science, developing a first-in-class ADC payload platform designed to overcome key limitations of existing ADCs, with potential across multiple solid tumour types.

How Steve Pollard created the Trojan horse of cancer treatments

A founder's perspective

“I was very lucky that Cancer Research UK supported me with a project grant, realising that these are good model systems.”
Steve Pollard, CSO and founder of Trogenix

Steve Pollard’s research into transcription factors driving brain development has been quite the ride. Now advances in viral gene delivery – and a £70m Series A, including Cancer Research Horizons' largest ever investment – have sent a highly targeted glioblastoma immunotherapy heading toward the clinic.

Learn more